Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response-Reference-Cited by-同舟云学术

Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response

Published:2021-10-20 Issue:616 Volume:13 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

De Gassart Aude¹^ORCID,Le Kieu-Suong¹^ORCID,Brune Patrick¹,Agaugué Sophie¹,Sims Jennifer²,Goubard Armelle³,Castellano Rémy³,Joalland Noémie⁴⁵,Scotet Emmanuel⁴⁵^ORCID,Collette Yves³^ORCID,Valentin Emmanuel¹^ORCID,Ghigo Clement¹,Pasero Christine¹^ORCID,Colazet Magali¹^ORCID,Guillén Jaime¹^ORCID,Cano Carla E.¹,Marabelle Aurélien⁶^ORCID,De Bonno Johann⁷^ORCID,Hoet René¹⁸,Truneh Alemseged¹,Olive Daniel⁹,Frohna Paul¹^ORCID

Affiliation:

1. ImCheck Therapeutics, 13009 Marseille, France.

2. Integrated Biologix GmbH, 4051 Basel, Switzerland.

3. Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET preclinical platform, 13009 Marseille, France.

4. Université de Nantes, INSERM, CNRS, CRCINA, F-44000 Nantes, France.

5. LabEx IGO “Immunotherapy, Graft, and Oncology,” Nantes F-44000, France.

6. Département d’Innovation Thérapeutique et d’Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France.

7. Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton SM2 5PT, UK.

8. Biopharmaceutics, Dept. Pathology, University of Maastricht, 6200 MD Netherlands.

9. Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France.

Abstract

ICT01, a humanized BTN3A mAb, activates Vγ9Vδ2 T cell antitumor immunity and is well tolerated and pharmacodynamically active in patients.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference55 articles.

1. γδ T Cells: First Line of Defense and Beyond

2. γδ T cells in tissue physiology and surveillance

3. Structure of a human γδ T-cell antigen receptor

4. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset

5. Cancer immunotherapy with γδ T cells: many paths ahead of us

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural killer cells and engagers: Powerful weapons against cancer;Immunological Reviews;2024-08-24

2. Randomized Phase 2 Trial of Lirilumab as maintenance Treatment in Acute Myeloid Leukemia: Results of the EFFIKIR Trial;2024-08-23

3. Phosphoantigen recognition by Vγ9Vδ2 T cells;European Journal of Immunology;2024-08-15

4. Low frequency of Vγ9Vδ2 T cells predicts poor survival in newly diagnosed acute myeloid leukemia;Blood Advances;2024-08-14

5. Dysfunctional tumor-infiltrating Vδ1 + T lymphocytes in microsatellite-stable colorectal cancer;Nature Communications;2024-08-13